Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
IPO Year: 2019
Exchange: NASDAQ
Website: progyny.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | $26.00 → $19.00 | Buy → Hold | Truist |
| 9/19/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | $37.00 → $24.00 | Buy → Hold | Canaccord Genuity |
| 8/7/2024 | $31.00 → $25.00 | Outperform → Market Perform | Leerink Partners |
| 8/7/2024 | Buy → Neutral | BTIG Research | |
| 7/16/2024 | $36.00 | Mkt Outperform | JMP Securities |
| 5/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 2/26/2024 | $49.00 | Outperform | Leerink Partners |
| 1/3/2024 | $48.00 | Overweight | Barclays |
| 9/27/2023 | $46.00 | Buy | Canaccord Genuity |
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST). A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a transformative fertility, family building and women's health benefits solution, trusted by th
Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended September 30, 2024 ("the third quarter of 2024") as compared to the three-month period ended September 30, 2023 ("the third quarter of 2023" or "the prior year period"). "The utilization r
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and usin
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended June 30, 2024 ("the second quarter of 2024") as compared to the three-month period ended June 30, 2023 ("the second quarter of 2023" or "the prior year period"). "The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healt
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today launched the 2024 Awareness, Hope, and Activism (AHA) Grant™. Black individuals face significant hurdles when trying to access fertility and family building care, including financial constraints, healthcare disparities, and social stigmas. This grant, now in its third year, aims to provide education, access to specialized treatment, financial assistance, and emotional support, helping to address these multifaceted barriers. Pr
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended June 30, 2024 after the close of the market on Tuesday, August 6, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the sa
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that it will host its inaugural Investor Day in New York City on Monday, August 12, 2024, from 9:00 A.M. Eastern Time until approximately 1:00 P.M. Eastern Time. Progyny's executives, along with other members of the senior leadership team, will present an overview of the Company's business and its growth opportunities. During the meeting, there will be time allotted for live Q&A as well. Due to space restrictions, the Company is prioritizing in-person attendance to no more than two representatives per firm. Accordi
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care. Progyny's global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny's services allow employers the flexibility to offer fertility and family building benefits that co
Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced its Founder and Executive Chairman, Gina Bartasi, will return as the company's CEO during a time of unprecedented growth. The Company recently shared that it expected to deliver revenue in the range of $225-$250 million for 2024 and is now profitable after years of significant investment into new clinic locations and proprietary technology. Bartasi succeed
Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously
JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform
Canaccord Genuity downgraded Progyny from Buy to Hold and set a new price target of $24.00 from $37.00 previously
BTIG Research downgraded Progyny from Buy to Neutral
Leerink Partners downgraded Progyny from Outperform to Market Perform and set a new price target of $25.00 from $31.00 previously
JMP Securities initiated coverage of Progyny with a rating of Mkt Outperform and set a new price target of $36.00
KeyBanc Capital Markets downgraded Progyny from Overweight to Sector Weight
Leerink Partners initiated coverage of Progyny with a rating of Outperform and set a new price target of $49.00
Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $48.00
Canaccord Genuity initiated coverage of Progyny with a rating of Buy and set a new price target of $46.00
Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest Services in Maternity and/or Menopause Programs in 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended September 30, 2024 ("the third quarter of 2024") as compared to the three-month period ended September 30, 2023 ("the third quarter of 2023" or "the prior year period"). "The utilization r
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended September 30, 2024 after the close of the market on Tuesday, November 12, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and usin
Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended June 30, 2024 ("the second quarter of 2024") as compared to the three-month period ended June 30, 2023 ("the second quarter of 2023" or "the prior year period"). "The rate of utilization in the second quarter was consistent with our expectations, indicating that the demand for treatment remains both healt
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended June 30, 2024 after the close of the market on Tuesday, August 6, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the sa
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three-month period ended March 31, 2024 ("the first quarter of 2024") as compared to the three-month period ended March 31, 2023 ("the first quarter of 2023" or "the prior year period"). "Utilization through the end of February was consistent with the record engagement we saw a year ago. However, March was modestly below our expectations, coinciding with the national conversations concerning fertility treatments and access to maternal healthcare following the Alab
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period ended March 31, 2024 after the close of the market on Thursday, May 9, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the sa
Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% GrowthAchieves 49% Growth in Adjusted EBITDA to Record $187.1 MillionIssues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a transformative fertility, family building and women's health benefits solution, today announced its financial results for the three- and twelve-month periods ended December 31, 2023 ("the fourth quarter of 2023" and "the full year", respectively) as compared to the three- and twelve-month periods December 31, 2022 ("the fourth quarter of 2022" and "the prior year perio
NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2023 after the close of the market on Tuesday, February 27, 2024. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.
Record Quarterly Revenue of $280.9 Million, Reflecting 37% Growth Over the Prior Year PeriodRaises Full Year Revenue and Earnings GuidanceStrong Sales Season Produces 1.3 Million New Covered Lives NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a leading benefits management company specializing in fertility and family building benefits solutions, today announced its financial results for the three-month period ended September 30, 2023 ("the third quarter of 2023") as compared to the three-month period ended September 30, 2022 ("the third quarter of 2022" or "the prior year period"). "We're pleased with our third quarter financ
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2023 after the close of the market on Tuesday, November 7, 2023. The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.9
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
4 - Progyny, Inc. (0001551306) (Issuer)
10-Q - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
10-Q - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
10-Q - Progyny, Inc. (0001551306) (Filer)
8-K - Progyny, Inc. (0001551306) (Filer)
Progyny (NASDAQ:PGNY) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.17, a high estimate of $48.00, and a low estimate of $30.00. This current average has decreased by 19.81% from the previous
JMP Securities analyst Constantine Davides initiates coverage on Progyny (NASDAQ:PGNY) with a Market Outperform rating and announces Price Target of $36.
This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care.
Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and lowers the price target from $46 to $37.
Cantor Fitzgerald analyst Sarah James reiterates Progyny (NASDAQ:PGNY) with a Overweight and maintains $48 price target.
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $48 to $30.
Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Buy and lowers the price target from $46 to $37.
On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of clients and covered lives. Fertility benefit services revenue was $169.8 million, an 8.0% increase from the $157.1 million reported in the first quarter of 2023. Pharmacy benefit services revenue was $108.3 million, a 7.0% increase compared to the $101.2 million reported in the first quarter of 2023. The company reported adjusted EPS of $0.39, up from $0.34 a year ago. The company had 451 clients as of March 31, 2024, compared to 379 a year ago. Assisted Reproductive Technology (ART) cycl
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
SC 13G/A - Progyny, Inc. (0001551306) (Subject)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform founded in 2019. This acquisition enhances Progyny's guided, concierge support that enables employees around the world to navigate the complexities of fertility and family building care. Progyny's global benefits solution supports multinational employers and their employee populations in over 100 countries. Progyny's services allow employers the flexibility to offer fertility and family building benefits that co
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced two newly created roles with the appointment of Katie Higgins as Chief Commercial Officer and Steven Leist as Chief Technology Officer. "We are excited to expand our executive team and welcome Katie and Steven to Progyny. Their expertise will further advance our growth and momentum in the fertility, family building, and women's health benefits space," said Pete Anevski, Progyny's CEO. With over 25 years of healthcare experience, Katie Higgins will be overseeing the teams that drive revenue, business growth, and client succes
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of Janet Choi, M.D., as the company's Chief Medical Officer. Dr. Choi brings more than 20 years of experience in the field as a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. In her new role, she will lead clinical strategy working closely with the company's executive team and medical advisory board to ensure Progyny offers the highest quality and most effective family building and women's health benefits possible. "I am thrilled to offici
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of a new member to its board of directors, effective August 30, 2022. Joining the board is Lloyd Dean, Chief Executive Emeritus and Founding Executive of CommonSpirit Health. "I am excited to welcome Lloyd to the Board and believe the value he brings from his experience on expanding access to healthcare will be an asset as we explore how we can further our reach when it comes to infertility and family building," said Pete Anevski, Chief Executive Officer of Progyny. "He brings compl
LOS ANGELES--(BUSINESS WIRE)--In line with its mission to create a reliable, elevated and technology-driven experience, Alchemy 43, which is currently raising a $10M Series B, announced today the hiring of Kimberly Joerger as the company’s new Chief Operating Officer, and Dr. Sarmela Sunder as its new Los Angeles Medical Director. Both will report directly to Nicci Levy, Founder and CEO of the revolutionary medical aesthetics brand that specializes in enhancement and prevention. Additionally, Alchemy 43 has added industry titan, Gina Bartasi to its Board of Directors. With a career that spans across both tech and retail sectors, Joerger comes most recently from Stitch Fix. During h